ER-dependent breast cancer cells develop resistance to aromatase inhibition through epigenetic and transcriptomic activation of cholesterol biosynthesis that contributes to aggressive breast phenotypes (165). This evidence concerns the gene CYP19A1 and breast carcinoma.